Brandon Folkes, an analyst from H.C. Wainwright, reiterated the Buy rating on PolyPid. The associated price target remains the same with $13.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Folkes has given his Buy rating due to a combination of factors that highlight PolyPid’s promising outlook. The company achieved significant milestones with the positive topline results from the Phase 3 SHIELD II trial of D-PLEX100, which demonstrated a substantial reduction in surgical site infections and other related complications compared to the standard of care. This success supports the clinical profile of D-PLEX100 and aligns with previous trial results, reinforcing its potential as a valuable treatment option.
Additionally, PolyPid is on track to submit a New Drug Application in early 2026, with preparations for commercialization already underway. The company is actively engaging in partnership discussions to facilitate the launch of D-PLEX100 in the U.S. market. Furthermore, PolyPid is advancing its GLP-1 receptor agonist delivery platform, targeting the obesity and diabetes markets, which could provide long-term growth opportunities. The appointment of a new Chief Medical Officer and the strengthening of its financial position through warrant exercises further bolster the company’s strategic initiatives.
According to TipRanks, Folkes is an analyst with an average return of -6.4% and a 33.46% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Omeros, Trevi Therapeutics, and Milestone Pharmaceuticals.